中文
EN
About us
Company Introduction
Corporate History
Business Introduction
Corporate Governance
Company Culture
Corporate Honors
R&D and Innovation
R&D
Innovation
Product Pipeline
Achievements
Products
Drug Products
Biological products
APIs
Intermediates
Boranes
OLED Materials
CDMO
Project Collaboration
In-/Out-Licensing
Joint Venture
Sustainable
EHS
Energy
Quality
Supplier
News Center
2024
2023
2022
2021
Join Us
Talent Philosophy
Talent Development
Salary and Benefits
Campus Recruiting
Social Recruitment
Contact Us
Online Message
Blog Center
In 2024
In 2023
In 2022
In 2021
In 2020
In 2019
In 2018
In 2017
In 2016
Viwit Pharmaceutical's Phenylephrine Hydrochloride Injection Officially Receives Official Approval by China NMPA
Viwit Pharmaceuticals’ Brimonidine tartrate and Timolol maleate eye drops receive Official Approval by China NMPA
Viwit's Nitroglycerin Sublingual Tablets Approved by FDA
Viwit Pharmaceuticals API Site Successfully Passed FDA cGMP On-site Audit with "No Action Indicated"
Viwit Pharmaceutical Co. Ltd. announces exclusive licensing and supply agreement for two Gadolinium based Magnetic Resonance Imaging (MRI) injectable contrast agents in the US.
Viwit Pharmaceutical’s Lifitegrast API has completed registrations in both China and the US!
Search
中文
EN
